Biogen Idec confirms SEC probe of trading before drug pulled

BOSTON (AP) - U.S. federal regulators are formally investigating possible securities laws violations related to Biogen Idec Inc.'s recent withdrawal of a multiple sclerosis drug, a move that sent the company's shares plunging....More